新型冠状病毒肺炎的预防和药物治疗进展  

Progress in prevention of COVID-19 and its medical treatment with antiviral drugs against SARS-CoV-2

作　　者：凌云 张丽荣 彭军 王立 LING Yun;ZHANG Lirong;PENG Jun;WANG Li(Department of Pharmacy,Hebei Yanda Hospital,Langfang Hebei 065201,China;Department of Respiratory and Critical Care Medicine,Hebei Yanda Hospital,Langfang Hebei 065201,China)

机构地区：[1]河北燕达医院药学部,河北廊坊065201 [2]河北燕达医院呼吸与危重症医学科,河北廊坊065201

出　　处：《转化医学杂志》2022年第3期192-194,F0003,187,共5页Translational Medicine Journal

基　　金：河北省医学科学研究课题(20200034)。

摘　　要：新型冠状病毒肺炎(Coronavirus disease 2019,COVID-19)是由严重急性呼吸道综合征冠状病毒2(severe acute respiratory symptom coronavirus 2,SARS-CoV-2)引起的急性呼吸道传染病,是近百年来人类遭遇的影响范围最广的全球性大流行病。预防COVID-19的3种措施分别为保持社交距离、佩戴口罩和疫苗接种。目前,SARSCoV-2已经变异到第5代的Omicron变异株,随着SARS-CoV-2的变异,传染性变强,毒力变弱,无症状和轻症居多,病死率下降,COVID-19正在流感化。随着口服抗SARS-CoV-2药的研发和上市,加上新冠疫苗的全面接种,全球的COVID-19疫情控制指日可待。Coronavirus disease 2019(COVID-19),which emerged in December 2019,is caused by severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)infection.The COVID-19 epidemic has made the world’s public system withstand extreme tests.Keeping social distances,masks,and vaccine administration are three important methods to prevent its infections.Now SARS-CoV-2 has mutated into Omicron variant of its five generations.Omicron has the characteristics of highly transmissibility,weak pathogenicity,mild cases,and low mortality.Along with COVID-19vaccination and development of orally antiviral drugs against SARS-CoV-2,COVID-19 epidemic can be controlled in near future.

关 键 词：新型冠状病毒肺炎 严重急性呼吸道综合征冠状病毒2 预防 药物治疗 

分 类 号：R563.1[医药卫生—呼吸系统] R969.3[医药卫生—内科学]